PA
ENTA icon

Parallel Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Parallel Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-51
Closed -$804 – 3871
2025
Q4 		$804 Buy
+51
New +$648 ﹤0.01% 3331
2023
Q3 		– Sell
-13
Closed -$278 – 3401
2023
Q2 		$278 Buy
+13
New +$383 ﹤0.01% 3203
2022
Q2 		– Sell
-164
Closed -$11K – 3075
2022
Q1 		$11K Sell
164
-587
-78% -$38.2K ﹤0.01% 1955
2021
Q4 		$56K Sell
751
-14
-2% -$1.1K ﹤0.01% 1259
2021
Q3 		$43K Buy
765
+667
+681% +$33K ﹤0.01% 1338
2021
Q2 		$4K Buy
98
+51
+109% +$2.5K ﹤0.01% 2356
2021
Q1 		$2K Hold
47
– – ﹤0.01% 2457
2020
Q4 		$2K Sell
47
-53
-53% -$2.33K ﹤0.01% 2294
2020
Q3 		$5K Buy
100
+65
+186% +$3.15K ﹤0.01% 2006
2020
Q2 		$1K Buy
+35
New +$1.81K ﹤0.01% 2308
2018
Q2 		– Sell
-348
Closed -$28K – 2117
2018
Q1 		$28K Buy
+348
New +$26.8K ﹤0.01% 874

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Parallel Advisors's ENTA Position: Q1 2026 in Review

Parallel Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q1 2026, closing a stake of 51 shares — an estimated $804 sold.

Parallel Advisors first reported a position in ENTA in Q1 2018 and held it in 11 quarters. The position peaked at $56K in Q4 2021. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Parallel Advisors reported no remaining Enanta Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Parallel Advisors sold 51 Enanta Pharmaceuticals shares in Q1 2026, an estimated $804.
  • Parallel Advisors first reported a position in Enanta Pharmaceuticals in Q1 2018 and held it in 11 quarters.
  • Parallel Advisors's Enanta Pharmaceuticals position peaked at $56K in Q4 2021.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.